ReviewJMA journal2021
Clinical Manifestations of Coronavirus Disease 2019.
Review in JMA journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.Emerging microbes & infections · 2022Pooled it
- Fever duration, peak temperature and associated symptoms in Chinese adults with SARS-CoV-2 infection: a cross-sectional study.Frontiers in medicine · 2025Article
- The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.Scientific reports · 2024Article
- Correlation between the hysteresis of the pressure-volume curve and the recruitment-to-inflation ratio in patients with coronavirus disease 2019.Annals of intensive care · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 is an infection caused by severe acute respiratory syndrome coronavirus 2. Many symptomatic patients have influenza-like symptoms such as fever, respiratory symptoms (cough, sore throat, and nasal discharge), headache, and malaise. In some cases, oxygen is required within a week of onset, and in more severe cases, the patient is admitted to the intensive care unit after around 10 days of onset. In the COVIREGI-JP registry of hospitalized patients with coronavirus disease 2019, patients with renal dysfunction, liver disease, obesity, hyperlipidemia, hypertension, and diabetes tended to be more severely ill after hospitalization than patients without comorbidities. It has also become clear that symptoms can persist even after the acute phase has passed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.